collection
MENU ▼
Read by QxMD icon Read
search

Diabetes

shared collection
65 papers 25 to 100 followers
https://www.readbyqxmd.com/read/28514615/bariatric-surgery-or-intensive-medical-therapy-for-diabetes-after-5-years
#1
LETTER
David L Howard
New England Journal of Medicine, Volume 376, Issue 20, Page 1995-1997, May 2017.
May 18, 2017: New England Journal of Medicine
https://www.readbyqxmd.com/read/28451823/bilateral-lower-limb-edema-induced-by-rapid-improvement-of-glycemic-control-with-insulin-therapy-in-a-subject-with-poorly-controlled-type-2-diabetes
#2
LETTER
Yuki Kan, Takatoshi Anno, Fumiko Kawasaki, Maiko Takai, Ryo Shigemoto, Hideaki Kaneto, Kohei Kaku, Niro Okimoto
No abstract text is available yet for this article.
April 27, 2017: Acta Diabetologica
https://www.readbyqxmd.com/read/28453780/variation-in-maturity-onset-diabetes-of-the-young-genes-influence-response-to-interventions-for-diabetes-prevention
#3
Liana K Billings, Kathleen A Jablonski, A Sofia Warner, Yu-Chien Cheng, Jarred B McAteer, Laura Tipton, Alan R Shuldiner, David A Ehrmann, Alisa K Manning, Dana Dabelea, Paul W Franks, Steven E Kahn, Toni I Pollin, William C Knowler, David Altshuler, Jose C Florez
CONTEXT: Variation in genes that cause Maturity-Onset Diabetes of the Young (MODY) has been associated with diabetes incidence and glycemic traits. OBJECTIVES: This study aimed to determine whether genetic variation in MODY genes leads to differential responses to insulin-sensitizing interventions. DESIGN AND SETTING: This was a secondary analysis of a multicenter randomized clinical trial, the Diabetes Prevention Program (DPP), involving 27 U...
April 27, 2017: Journal of Clinical Endocrinology and Metabolism
https://www.readbyqxmd.com/read/28364357/treatment-of-diabetic-ketoacidosis-dka-hyperglycemic-hyperosmolar-state-hhs-novel-advances-in-the-management-of-hyperglycemic-crises-uk-versus-usa
#4
REVIEW
Ketan K Dhatariya, Priyathama Vellanki
PURPOSE OF REVIEW: Diabetic ketoacidosis (DKA) and hyperglycemic hyperosmolar state (HHS) are diabetic emergencies that cause high morbidity and mortality. Their treatment differs in the UK and USA. This review delineates the differences in diagnosis and treatment between the two countries. RECENT FINDINGS: Large-scale studies to determine optimal management of DKA and HHS are lacking. The diagnosis of DKA is based on disease severity in the USA, which differs from the UK...
May 2017: Current Diabetes Reports
https://www.readbyqxmd.com/read/28404659/early-glycemic-control-and-magnitude-of-hba1c-reduction-predict-cardiovascular-events-and-mortality-population-based-cohort-study-of-24-752-metformin-initiators
#5
Elisabeth Svensson, Lisbeth M Baggesen, Søren P Johnsen, Lars Pedersen, Helene Nørrelund, Esben S Buhl, Christiane L Haase, Reimar W Thomsen
OBJECTIVE: We investigated the association of early achieved HbA1c level and magnitude of HbA1c reduction with subsequent risk of cardiovascular events or death in patients with type 2 diabetes who initiate metformin. RESEARCH DESIGN AND METHODS: This was a population-based cohort study including all metformin initiators with HbA1c tests in Northern Denmark, 2000-2012. Six months after metformin initiation, we classified patients by HbA1c achieved (<6.5% or higher) and by magnitude of HbA1c change from the pretreatment baseline...
April 12, 2017: Diabetes Care
https://www.readbyqxmd.com/read/28381450/management-of-endocrine-disease-pathogenesis-and-management-of-hypoglycemia
#6
Nana Esi Kittah, Adrian Vella
Glucose is the main substrate utilized by the brain and as such multiple regulatory mechanisms exist to maintain glucose concentrations. When these mechanisms fail or are defective hypoglycemia ensues. Due to these robust mechanisms hypoglycemia is uncommon and usually occurs in the setting of the treatment of diabetes using glucose- lowering agents such as sulfonylureas or insulin. The symptoms of hypoglycemia are non-specific and as such it is important to confirm hypoglycemia by establishing the presence of Whipple's triad prior to embarking on an evaluation for hypoglycemia...
April 5, 2017: European Journal of Endocrinology
https://www.readbyqxmd.com/read/28325800/is-hba1c-7-a-marker-of-poor-performance-in-individuals-65-years-old
#7
Zachary T Bloomgarden, Daniel Einhorn, Yehuda Handelsman
No abstract text is available yet for this article.
April 2017: Diabetes Care
https://www.readbyqxmd.com/read/28325795/the-pathophysiology-of-hyperglycemia-in-older-adults-clinical-considerations
#8
REVIEW
Pearl G Lee, Jeffrey B Halter
Nearly a quarter of older adults in the U.S. have type 2 diabetes, and this population is continuing to increase with the aging of the population. Older adults are at high risk for the development of type 2 diabetes due to the combined effects of genetic, lifestyle, and aging influences. The usual defects contributing to type 2 diabetes are further complicated by the natural physiological changes associated with aging as well as the comorbidities and functional impairments that are often present in older people...
April 2017: Diabetes Care
https://www.readbyqxmd.com/read/28325798/management-of-inpatient-hyperglycemia-and-diabetes-in-older-adults
#9
Guillermo E Umpierrez, Francisco J Pasquel
Adults aged 65 years and older are the fastest growing segment of the U.S. population, and their number is expected to double to 89 million between 2010 and 2050. The prevalence of diabetes in hospitalized adults aged 65-75 years and over 80 years of age has been estimated to be 20% and 40%, respectively. Similar to general populations, the presence of hyperglycemia and diabetes in elderly patients is associated with increased risk of hospital complications, longer length of stay, and increased mortality compared with subjects with normoglycemia...
April 2017: Diabetes Care
https://www.readbyqxmd.com/read/28288484/pharmacologic-therapy-for-type-2-diabetes-synopsis-of-the-2017-american-diabetes-association-standards-of-medical-care-in-diabetes
#10
James J Chamberlain, William H Herman, Sandra Leal, Andrew S Rhinehart, Jay H Shubrook, Neil Skolnik, Rita Rastogi Kalyani
Description: The American Diabetes Association (ADA) annually updates the Standards of Medical Care in Diabetes to provide clinicians, patients, researchers, payers, and other interested parties with evidence-based recommendations for the diagnosis and management of patients with diabetes. Methods: For the 2017 Standards, the ADA Professional Practice Committee updated previous MEDLINE searches performed from 1 January 2016 to November 2016 to add, clarify, or revise recommendations based on new evidence...
April 18, 2017: Annals of Internal Medicine
https://www.readbyqxmd.com/read/28223503/mitochondrial-energy-deficiency-leads-to-hyperproliferation-of-skeletal-muscle-mitochondria-and-enhanced-insulin-sensitivity
#11
Ryan M Morrow, Martin Picard, Olga Derbeneva, Jeremy Leipzig, Meagan J McManus, Gilles Gouspillou, Sébastien Barbat-Artigas, Carlos Dos Santos, Russell T Hepple, Deborah G Murdock, Douglas C Wallace
Diabetes is associated with impaired glucose metabolism in the presence of excess insulin. Glucose and fatty acids provide reducing equivalents to mitochondria to generate energy, and studies have reported mitochondrial dysfunction in type II diabetes patients. If mitochondrial dysfunction can cause diabetes, then we hypothesized that increased mitochondrial metabolism should render animals resistant to diabetes. This was confirmed in mice in which the heart-muscle-brain adenine nucleotide translocator isoform 1 (ANT1) was inactivated...
March 7, 2017: Proceedings of the National Academy of Sciences of the United States of America
https://www.readbyqxmd.com/read/28223445/diabetic-retinopathy-a-position-statement-by-the-american-diabetes-association
#12
REVIEW
Sharon D Solomon, Emily Chew, Elia J Duh, Lucia Sobrin, Jennifer K Sun, Brian L VanderBeek, Charles C Wykoff, Thomas W Gardner
No abstract text is available yet for this article.
March 2017: Diabetes Care
https://www.readbyqxmd.com/read/28167928/clinical-review-of-antidiabetic-drugs-implications-for-type-2-diabetes-mellitus-management
#13
REVIEW
Arun Chaudhury, Chitharanjan Duvoor, Vijaya Sena Reddy Dendi, Shashank Kraleti, Aditya Chada, Rahul Ravilla, Asween Marco, Nawal Singh Shekhawat, Maria Theresa Montales, Kevin Kuriakose, Appalanaidu Sasapu, Alexandria Beebe, Naveen Patil, Chaitanya K Musham, Govinda Prasad Lohani, Wasique Mirza
Type 2 diabetes mellitus (T2DM) is a global pandemic, as evident from the global cartographic picture of diabetes by the International Diabetes Federation (http://www.diabetesatlas.org/). Diabetes mellitus is a chronic, progressive, incompletely understood metabolic condition chiefly characterized by hyperglycemia. Impaired insulin secretion, resistance to tissue actions of insulin, or a combination of both are thought to be the commonest reasons contributing to the pathophysiology of T2DM, a spectrum of disease originally arising from tissue insulin resistance and gradually progressing to a state characterized by complete loss of secretory activity of the beta cells of the pancreas...
2017: Frontiers in Endocrinology
https://www.readbyqxmd.com/read/27849359/basal-insulin-4-0-updating-your-clinical-practice-with-ultralong-acting-insulins-and-insulin-combination-therapy
#14
(no author information available yet)
No abstract text is available yet for this article.
November 2016: Endocrine Practice
https://www.readbyqxmd.com/read/27605513/neonatal-hypoglycemia
#15
REVIEW
David H Adamkin
A consistent definition for neonatal hypoglycemia in the first 48 h of life continues to elude us. Enhanced understanding of metabolic disturbances and genetic disorders that underlie alterations in postnatal glucose homeostasis has added useful information to understanding transitional hypoglycemia. This growth in knowledge still has not led to what we need to know: "How low is too low and for how long?" This article reviews the current state of understanding of neonatal hypoglycemia and how different approaches reach different "expert" opinions...
February 2017: Seminars in Fetal & Neonatal Medicine
https://www.readbyqxmd.com/read/28140674/concentrated-insulins-clinical-applications-use-in-practical-settings
#16
(no author information available yet)
No abstract text is available yet for this article.
January 2, 2017: Endocrine Practice
https://www.readbyqxmd.com/read/28108536/dpp-4-inhibitor-related-pancreatitis-rare-but-real
#17
J Hans DeVries, Julio Rosenstock
No abstract text is available yet for this article.
February 2017: Diabetes Care
https://www.readbyqxmd.com/read/28088910/sodium-glucose-cotransporter-2-inhibitors-sglt2i-their-role-in-cardiometabolic-risk-management
#18
Niki Katsiki, Dimitri P Mikhailidis, Michael J Theodorakis
BACKGROUND: Sodium-glucose cotransporter 2 inhibitors (SGLT2i) are a novel category of oral antidiabetic drugs that inhibit renal glucose reabsorption and increase renal glucose excretion, thus lowering plasma glucose levels. This unique mechanism of SGLT2i action is insulin independent, thus improving glycemic control without promoting hypoglycemia in the absence of exogenously administered insulin. METHODS: The present narrative review addresses the putative associations between SGLT2i and several cardiovascular (CV) and microvascular risk factors, as well as their effects on cardiac and renal function...
January 13, 2017: Current Pharmaceutical Design
https://www.readbyqxmd.com/read/28057658/pioglitazone-and-cardiovascular-outcomes-in-patients-with-insulin-resistance-pre-diabetes-and-type-2-diabetes-a-systematic-review-and-meta-analysis
#19
Hung-Wei Liao, Jeffrey L Saver, Yi-Ling Wu, Tso-Hsiao Chen, Meng Lee, Bruce Ovbiagele
OBJECTIVES: To evaluate the effect of pioglitazone in people with insulin resistance, pre-diabetes and type 2 diabetes. DESIGN AND SETTING: Systematic review and meta-analysis of randomised, controlled trials. DATA SOURCES: Literature searches were performed across PubMed, EMBASE, MEDLINE and Cochrane Central Register of Controlled Trials from 1966 to May 2016 to identify randomised, controlled trials with more than 1 year follow-up. OUTCOME MEASURES: Relative risk (RR) with 95% CI was used to evaluate the association between pioglitazone and the risk of major adverse cardiovascular events (MACE: composite of non-fatal myocardial infarction, non-fatal stroke and cardiovascular death) and safety outcomes, after pooling data across trials in a fixed-effects model...
January 5, 2017: BMJ Open
https://www.readbyqxmd.com/read/28095040/consensus-statement-by-the-american-association-of-clinical-endocrinologists-and-american-college-of-endocrinology-on-the-comprehensive-type-2-diabetes-management-algorithm-2017-executive-summary
#20
Alan J Garber, Martin J Abrahamson, Joshua I Barzilay, Lawrence Blonde, Zachary T Bloomgarden, Michael A Bush, Samuel Dagogo-Jack, Ralph A DeFronzo, Daniel Einhorn, Vivian A Fonseca, Jeffrey R Garber, W Timothy Garvey, George Grunberger, Yehuda Handelsman, Irl B Hirsch, Paul S Jellinger, Janet B McGill, Jeffrey I Mechanick, Paul D Rosenblit, Guillermo E Umpierrez
A1C = hemoglobin A1C AACE = American Association of Clinical Endocrinologists ACCORD = Action to Control Cardiovascular Risk in Diabetes ACCORD BP = Action to Control Cardiovascular Risk in Diabetes Blood Pressure ACEI = angiotensin-converting enzyme inhibitor ADVANCE = Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation AGI = alpha-glucosidase inhibitor apo B = apolipoprotein B ASCVD = atherosclerotic cardiovascular disease BAS = bile acid sequestrant BMI = body mass index BP = blood pressure CHD = coronary heart disease CKD = chronic kidney disease CVD = cardiovascular disease DASH = Dietary Approaches to Stop Hypertension DPP-4 = dipeptidyl peptidase 4 eGFR = estimated glomerular filtration rate FDA = Food and Drug Administration GLP-1 = glucagon-like peptide 1 HDL-C = high-density lipoprotein cholesterol IMPROVE-IT = Improved Reduction of Outcomes: Vytorin Efficacy International Trial LDL-C = low-density lipoprotein cholesterol LDL-P = low-density lipoprotein particle Look AHEAD = Look Action for Health in Diabetes NPH = neutral protamine Hagedorn OSA = obstructive sleep apnea SFU = sulfonylurea SGLT-2 = sodium glucose cotransporter-2 SMBG = self-monitoring of blood glucose T2D = type 2 diabetes TZD = thiazolidinedione VADT = Veterans Affairs Diabetes Trial...
February 2017: Endocrine Practice
label_collection
label_collection
7266
1
2
2017-01-28 11:27:54
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"